What is it for: Used in the treatment of patients with advanced renal cell cancer when standard therapy has not helped to stop the disease or is considered unsuitable.

Why is it better: Trials have shown that sorafenib can make the cancer stop growing for longer than people taking a placebo. It has also been found to slow the growth of advanced kidney cancer.

When was it licensed: The European Commission approved the use of sorafenib for advanced renal cell cancer in 2006.

When will it be appraised by Nice: The drug is on the list of provisional appraisal topics produced by the Department of Health. The All Wales Medicines Group appraised it, refusing funding, last week.